Skip to main content
Relay Therapeutics, Inc. logo

Relay Therapeutics, Inc. — Investor Relations & Filings

Ticker · RLAY ISIN · US75943R1023 US Manufacturing
Open in API
Filings indexed 484 across all filing types
Latest filing 2022-09-29 Director's Dealing
Country US United States of America
Listing US RLAY

About Relay Therapeutics, Inc.

https://relaytx.com/

Relay Therapeutics, Inc. is a clinical-stage precision medicines company focused on transforming the drug discovery process. The company's approach is centered on understanding protein motion, utilizing its proprietary Dynamo® platform which integrates advanced computational and experimental methods. This platform enables the visualization of protein dynamics to design novel therapies for targets that have been historically considered intractable or 'undruggable'. Relay Therapeutics is advancing a pipeline of therapeutic candidates with an initial focus on precision oncology and genetic diseases.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2022-09-29 English
FORM 4 SUBMISSION
Director's Dealing
2022-09-16 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to an underwritten public offering of common stock, including details about the underwriting agreement, pricing, and expected proceeds. It also includes references to press releases about the offering launch and pricing. The document does not contain financial statements or detailed financial analysis but rather announces a financing event. According to the filing definitions, updates on company fundraising or financing activities fall under Capital/Financing Update (CAP). Therefore, this document is best classified as a Capital/Financing Update (CAP). The document length (7922 characters) and detailed description support this classification with high confidence.
2022-09-15 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under a registration statement, describing an offering of common stock. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and company overview. This type of document is related to capital raising activities and financing. It is not an annual report, earnings release, or any other financial report but a capital/financing update related to a stock offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full prospectus supplement, not just an announcement or a brief notice.
2022-09-13 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement and accompanying prospectus related to an offering of $300 million of common stock by the company Relay Therapeutics, Inc. It includes detailed information about the offering, risk factors, use of proceeds, underwriting, and company overview. The document is filed pursuant to Rule 424(b)(5), which is a prospectus supplement filing related to securities offerings. This type of document is a capital/financing update as it provides details about the company's fundraising through a stock offering. It is not an annual report, earnings release, or any other report type. The length and content confirm it is a detailed financing document rather than a brief announcement or regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-09-12 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text includes a detailed announcement of interim clinical data from a trial, a press release, and a corporate presentation. It does not contain comprehensive financial statements or annual/quarterly report data. The document is not an earnings release, proxy, or management discussion. It is a regulatory filing reporting a material event (clinical trial data release) and related disclosures. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-09-12 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.